Core Insights - Medicus Pharma Ltd. reported independent clinical validation of its Phase 2 SkinJect® dataset, indicating that a majority of lesions in non-melanoma skin cancer patients may avoid immediate surgery [1][2] Clinical Study Findings - The SKNJCT-003 study is a randomized, double-blind, three-arm Phase 2 trial evaluating microneedle-mediated delivery of doxorubicin in patients with nodular basal cell carcinoma (BCC) [3] - The study design allows for a clear separation between active drug and device-only control, demonstrating a clinically meaningful therapeutic effect [3] - The 200µg dose cohort at Day 57 showed the highest observed activity, with approximately 75% of treated lesions potentially achieving visual tumor clearance [4] Treatment Implications - The findings suggest that SkinJect® could serve as a non-surgical treatment alternative, allowing many patients to avoid immediate surgical intervention [4] - The overall response rate was approximately 80%, with 73% clinical clearance and 40% histological clearance observed [5] Market Opportunity - Medicus Pharma's key therapeutic asset, SkinJect™, targets non-melanoma skin diseases, particularly BCC and Gorlin Syndrome, representing an estimated market opportunity of around $2 billion [12] - The company is also developing Teverelix, a next-generation GnRH antagonist for advanced prostate cancer, with a market opportunity of approximately $6 billion [13] Collaborations and Strategic Initiatives - Medicus Pharma announced a strategic collaboration with the Gorlin Syndrome Alliance to provide access to SkinJect for patients with Gorlin Syndrome [15][16] - The company is exploring co-development opportunities with Helix Nanotechnologies for infectious disease vaccines using its microneedle array delivery platform [13][14] - An AI-driven clinical data analytics platform is being developed in collaboration with Reliant AI Inc. to enhance clinical development efficiency [17]
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate